Abstract: A secure and trusted three-party device fingerprint authentication method is disclosed. The method includes the following steps: S1. authentication preparation stage: dividing subjects involved in fingerprint authentication into a device party U, a service party P and a storage party V, uploading and verifying an execution program of a trusted execution environment TEE; S2. authentication initialization stage: establishing the trusted execution environment TEE by the service party P, and establishing a security channel between the trusted execution environment TEE, the device party U and the storage party V; and S3. device fingerprint authentication stage: uploading a fingerprint and a fingerprint library to the trusted execution environment TEE through the security channel by the device party U and the storage party V, respectively, after completing a device fingerprint authentication, obtaining an authentication result through the security channel.

Abstract: A secure and trusted three-party device fingerprint authentication method is disclosed. The method includes the following steps: S1. authentication preparation stage: dividing subjects involved in fingerprint authentication into a device party U, a service party P and a storage party V, uploading and verifying an execution program of a trusted execution environment TEE; S2. authentication initialization stage: establishing the trusted execution environment TEE by the service party P, and establishing a security channel between the trusted execution environment TEE, the device party U and the storage party V; and S3. device fingerprint authentication stage: uploading a fingerprint and a fingerprint library to the trusted execution environment TEE through the security channel by the device party U and the storage party V, respectively, after completing a device fingerprint authentication, obtaining an authentication result through the security channel.

Abstract: It is provided a method of treatment of a human or animal patient in need thereof to achieve a reduction of the viscosity of mucus of the patient which is carried out by administering a polyglycerol derivative having a linear or dendritic polyglycerol backbone and carrying at least one thiol group covalently bound to the polyglycerol backbone. It is further provided a method of treatment of a human or animal patient suffering from chronic sinusitis, asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, emphysema, bronchiectasis, chronic inflammatory bowel diseases, constipation, gastrointestinal malabsorption syndrome, irritable bowel syndrome, steatorrhea or diarrhea by administering a polyglycerol derivative. Further specific thiol-functionalized polyglycerol derivatives and a corresponding manufacturing method are provided.

Abstract: Disclosed are a hyaluronic acid-based amphiphilic polymer, preparation method and application thereof. A main chain of the amphiphilic polymer is a hydrophilic hyaluronic acid and can be employed in active targeting, and a side chain thereof is a hydrophobic group represented by Formula (1). The amphiphilic polymer can carry a small molecule anticancer drug. Polymer nanoparticles are obtained via chemical crosslinking, such that the nanoparticles are not readily dissociated outside a cell or in blood, thus ensuring the stability of a drug encapsulated by the nanoparticles. Upon arriving at a tumor tissue, the hyaluronic acid on a surface of the nanoparticle can immediately combine with a CD44 receptor on a surface of a tumor cell, and effectively enter the tumor cell via endocytosis mediated by the receptor, and then quickly de-crosslink to be dissociated.

Abstract: Disclosed are a hyaluronic acid-based amphiphilic polymer, preparation method and application thereof. A main chain of the amphiphilic polymer is a hydrophilic hyaluronic acid and can be employed in active targeting, and a side chain thereof is a hydrophobic group represented by Formula (1). The amphiphilic polymer can carry a small molecule anticancer drug. Polymer nanoparticles are obtained via chemical crosslinking, such that the nanoparticles are not readily dissociated outside a cell or in blood, thus ensuring the stability of a drug encapsulated by the nanoparticles. Upon arriving at a tumor tissue, the hyaluronic acid on a surface of the nanoparticle can immediately combine with a CD44 receptor on a surface of a tumor cell, and effectively enter the tumor cell via endocytosis mediated by the receptor, and then quickly de-crosslink to be dissociated.